COMMUNIQUÉS West-GlobeNewswire

Emisphere Development Update
26/11/2018
ROSELAND, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced the completion and results on Thursday, November 22 and Friday, November 23 regarding their Pioneer 9 and Pioneer 6 phase 3a trials, both [...]
CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize
26/11/2018
Honored for his groundbreaking research on the determinants of longevity in human centenarians and associated models MENLO PARK, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage [...]
NRC Health Awards Annual Scholarship to UNL Students
26/11/2018
NRC Health awards Rising Stars Scholarship to successful business students and will recognize accomplishments at celebratory dinner LINCOLN, Neb., Nov. 26, 2018 (GLOBE NEWSWIRE) -- NRC Health is pleased to announce [...]
Valens GroWorks Focused on the (Near) Future of the Cannabis Industry -- CFN Media
26/11/2018
SEATTLE, Nov. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
Advantis Corp Attended the MjBizCon in Las Vegas Last Week and Took the Opportunity to Network with Current and Future Clients and Partners
26/11/2018
NEWPORT BEACH, CA, Nov. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ADVANTIS CORPORATION (OTC PINK: ADVT) attended the MjBizCon in Las Vegas last week and took the opportunity to network with current and future [...]
Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
26/11/2018
Topline results for Phase III MicroStat program expected H1 2019 NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of [...]
Tetra Bio-Pharma’s Dr. Chamberland Goes to Washington!
26/11/2018
ORLEANS, Ontario, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market that Dr. Guy [...]
Teladoc Health Launches Solution to Address Rising Prescription Drug Costs in Canada
26/11/2018
Using advanced analytics, Best Doctors Specialty Pharmacy Services helps employers and insurers identify and help members who would benefit from an expert medical opinion TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- [...]
Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
26/11/2018
Media Release Event to be held live in San Diego, California Independent experts to discuss data presented at the 2018 ASH Annual Meeting Meeting to be webcast live and archived on www.genmab.com Copenhagen, Denmark; [...]
SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients
26/11/2018
Data Expected in Fourth Quarter of 2019 Second Clinical Study of Nelipepimut-S Plus Trastuzumab After Recently Announced Positive Phase 2b Study in Low-expression HER2 or Triple Negative Breast Cancer Study supported by [...]
Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer
26/11/2018
CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today [...]
Novo Nordisk A/S - Share repurchase programme
26/11/2018
Bagsværd, Denmark, 26 November 2018 - On 5 November 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting
26/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug [...]
ITL Pharma Receives United States Patent Protection for Carcinin® Using Halogenated Phenol Ethers for Diagnostics, Antioxidant Protection and Drug Delivery
26/11/2018
KINGSPORT, Tenn., Nov. 26, 2018 (GLOBE NEWSWIRE) -- ITL Pharma, Inc. (ITL), a LIAS Company, today announced awarding of a United States Patent allowance (S.N. 15/336,179) titled: "Halogenated Phenols for Diagnostic, [...]
Zogenix to Announce New Data at 72nd American Epilepsy Society Annual Meeting
26/11/2018
Full Results from Second Pivotal Phase 3 Trial of FINTEPLA ® (ZX008) in Dravet Syndrome (Study 1504) New Long-Term Efficacy and Safety Data from Open-Label Extension Trial (Study 1503) Studies on the Impact of Severe [...]
Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis
26/11/2018
Data Expected in Second Half of 2019 CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a clinical-stage biotechnology company developing monoclonal microbials to engage [...]
SoldierStrong Announces 2018 SoldierScholar Recipients
26/11/2018
STAMFORD, Conn., Nov. 26, 2018 (GLOBE NEWSWIRE) -- SoldierStrong, a nonprofit organization dedicated to providing advanced medical technologies to veterans, today announced the 2018 recipients of its SoldierScholar [...]
InMode Receives Notice from the FDA of Satisfactory Address of the FDA Letter
26/11/2018
LAKE FOREST, Calif. and YOKNEAM, Israel, Nov. 26, 2018 (GLOBE NEWSWIRE) -- InMode Ltd. announced today that the FDA has advised the company of satisfactory address of all items that appeared in the ‘It Has Come to Our [...]
Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer
26/11/2018
CALGARY, Alberta and SAN DIEGO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced [...]

Pages